Biotech VC Funds

The Silicon Valley Technology Council (SVTC) operates as a key hub for fostering innovation and investment within the tech sector, particularly in the heart of Silicon Valley. With a strong focus on deep technology, SVTC aligns itself with the latest advancements in sectors like AI, quantum computing, and biotechnology. They work closely with tech leaders to address industry needs, supporting developments that can disrupt traditional models and foster significant growth. Their activities are driven by a mission to propel cutting-edge research into scalable businesses, ensuring the region remains a leader in global innovation. SVTC actively supports startups through partnerships and advocacy, emphasizing areas such as sustainability, ethical AI, and cybersecurity. They push for favorable regulatory environments that can accelerate the deployment of technologies like autonomous vehicles and clean energy solutions. By bringing together public and private stakeholders, the council ensures that Silicon Valley's tech ecosystem remains robust and well-connected. Furthermore, SVTC engages in promoting diversity and education, striving to enhance the local talent pool while also advocating for inclusive immigration policies to attract global tech expertise. Their recent initiatives include policy recommendations on AI, boosting funding for scientific research, and creating pathways for sustainable tech innovations. The council remains a pivotal player, providing insights, networking, and advocacy to ensure that Silicon Valley continues to be synonymous with tech entrepreneurship and growth.

The 100+ Accelerator was launched in 2018 by AB InBev and is now co-sponsored by major global companies like Coca-Cola, Colgate-Palmolive, Danone, and Unilever. This initiative is designed to support sustainability startups that align with the UN’s Sustainable Development Goals (SDGs). The program provides selected startups with up to $100,000 in funding for pilot projects that address sustainability challenges in sectors such as circular economy, water stewardship, sustainable agriculture, climate action, and biodiversity. The accelerator runs a six-month remote program where startups receive mentorship from industry experts, training, and opportunities to collaborate with these major corporations. The goal is to help startups validate their solutions through pilot projects and eventually scale them through long-term commercial contracts. Over 148 startups from 38 countries have participated in the program​. Startups that successfully complete the program are positioned to significantly impact global supply chains, and the accelerator’s Demo Day offers opportunities to pitch to world-class investors.

10X Capital is a versatile alternative asset management firm headquartered in New York City, specializing in providing institutional investors access to high-growth opportunities across various asset classes. Founded by Hans Thomas and co-headed by David Weisburd, the firm aligns Wall Street with Silicon Valley, focusing on venture capital, private credit, private equity, and real estate investments. 10X Capital’s notable strategies include venture capital investments in high-growth technology companies through private equity and public markets. They also manage SPACs, IPOs, and securitization, leveraging a deep network and robust analytical capabilities to identify and nurture promising startups. The firm has successfully facilitated the growth of several technology-driven businesses, effectively bridging the gap between institutional capital and innovative ventures​. Key team members include Russell Read, Chief Investment Officer, who brings extensive experience from CalPERS and the Alaska Permanent Fund, and Guhan Kandasamy, Chief Data Officer, known for his expertise in credit risk and data management. The team’s diverse background enables 10X Capital to provide comprehensive support and strategic insights to their portfolio companies​​. The firm’s mission is to democratize access to capital markets, ensuring that high-potential ventures receive the necessary funding and support to scale efficiently. This commitment is evident in their broad range of services and their strategic focus on sectors like technology, real estate, and specialty finance

11.2 Capital is an early-stage venture capital firm based in San Francisco, focusing on breakthrough technologies in artificial intelligence, augmented reality/virtual reality (AR/VR), robotics, space, and data-driven health. They have built a diverse portfolio that includes companies such as Bay Labs, Deep Genomics, and Hinge Health. Their investment strategy centers on early-stage technology startups with the potential for significant impact. 11.2 Capital has made 51 investments, with notable exits including Cruise Automation and Kindred AI. They emphasize supporting companies that leverage data at molecular and behavioral levels to innovate in healthcare, such as Apixio and Hindsait, which use data to enhance patient care and reduce costs. The firm is led by a team with deep expertise in technology and investment. Shelley Zhuang, a notable figure in the venture capital world, brings extensive knowledge in cybersecurity and AI. 11.2 Capital's approach involves not only providing capital but also strategic support to help startups scale effectively. Overall, 11.2 Capital is dedicated to fostering innovation in tech-driven sectors, providing both financial backing and strategic partnerships to enable startups to reach their full potential​.

13 Ventures is a U.S.-based venture capital fund specializing in consumer-facing companies that are already generating revenue and are on a strong growth trajectory. The fund is particularly interested in businesses that demonstrate a clear path to profitability, aiming to back scalable models that can quickly capitalize on market opportunities. While their check sizes and deal specifics are not publicized, they focus on later stages, supporting companies in growing their market presence and operational capacity. Startups are encouraged to have a strong product-market fit and be ready for strategic scaling before approaching the fund. The fund emphasizes the importance of introductions, signaling that they prefer startups to come through a trusted network or via direct recommendations. They value concise and well-prepared pitches that highlight key business metrics such as revenue growth and market positioning. The goal is to ensure each company aligns with 13 Ventures' investment thesis, which centers around robust consumer-driven companies poised for significant expansion. 13 Ventures offers more than just capital; they provide hands-on support to help their portfolio companies overcome operational and growth challenges. Their experience and extensive network provide startups with access to critical resources, including mentorship and partnerships that can accelerate growth. Their ideal investments are in companies that have already proven their ability to generate revenue and are ready to scale to the next level, with a firm foundation and potential for profitability. This focus on high-growth consumer markets sets 13 Ventures apart as a key player in helping companies scale effectively.

1517 Fund, co-founded in 2015 by Michael Gibson and Danielle Strachman, is a venture capital firm with a distinctive focus on backing young founders, dropouts, and renegade scientists. The firm is inspired by the spirit of Martin Luther's 1517 Reformation, challenging the conventional education system and supporting innovators working outside traditional academic tracks. 1517 Fund invests in early-stage startups, including those at the R&D/idea phase up to the Seed stage. They are particularly interested in software, hardware with a data play, deep tech/science fiction tech, and biotech. Their initial investments range from $50,000 to $1,000,000, with an average check size of around $400,000 for pre-seed investments. Notable companies in 1517 Fund's portfolio include Luminar, Lambda, Deepgram, and Figma. They have a community-oriented approach, providing grants, investments, and support to a network of hackers, makers, and scientists globally. This community includes events, workshops, and office hours aimed at fostering innovation and advancing the edges of knowledge and science. The fund's co-founders, Michael Gibson and Danielle Strachman, previously worked with Peter Thiel on the Thiel Fellowship, which provided $100k grants to young entrepreneurs, leading to successful ventures like Ethereum and OYO Rooms. This background underscores their commitment to nurturing unconventional talent and groundbreaking ideas.

1Up Ventures is a venture capital fund dedicated to supporting independent game developers. Founded by Ed Fries, a former Microsoft executive who played a pivotal role in the development of the Xbox, the fund is based in Kirkland, Washington. 1Up Ventures emphasizes building a diverse and inclusive community of talented, experienced, and creative indie game developers. The fund focuses exclusively on investing in game and content-focused studios, not platforms or tech-focused studios. 1Up Ventures typically does not act as a lead investor but supports founders through a community-driven approach. They invest a standard amount and percentage in their portfolio companies, emphasizing collaborative success. Key team members include Kelly Wallick, a partner and community builder who is also the founder of Indie MEGABOOTH, and Chris Wheaton, the fund administrator with extensive industry experience as a CFO, COO, and General Manager. The fund's portfolio features a variety of innovative game development studios, reflecting their commitment to a broad and inclusive portfolio approach.

2048 Ventures is a venture capital firm founded in 2018 and headquartered in New York, NY. The firm focuses on early-stage investments, particularly in technology-driven startups. They have a strong portfolio with over 120 investments across diverse sectors, including biotechnology, artificial intelligence, health tech, and commercial products. Some notable companies backed by 2048 Ventures include Adaptis Technologies, an AI-powered platform for optimizing the carbon footprint of buildings, and Fathom Optics, which delivers 3D experiences using standard printing technologies. Their investment strategy is to support visionary founders at the earliest stages, often leading pre-seed and seed rounds. 2048 Ventures has shown significant activity, with their portfolio companies collectively raising $591 million and reaching a valuation of $2.6 billion by the end of 2023. They have invested in innovative companies like TwoStep Therapeutics, which specializes in modular peptide technology for targeting solid tumors, and Century Health, which leverages AI to accelerate drug development​.

2150 is a London, Copenhagen, and Berlin-based venture capital firm focused on transforming urban environments through sustainable technology. With a €268 million fund, 2150 invests in companies that address major challenges across the "Urban Stack"—everything from the design and construction of cities to how they are powered and maintained. Their mission is to support groundbreaking startups that can reimagine urban living, while significantly reducing carbon emissions and improving sustainability. 2150 primarily invests in Series A and B stage companies, with check sizes ranging from $1 million to $7 million. Their focus spans climate tech, green solutions, and innovative materials, all aimed at creating smarter, more efficient cities. The firm’s portfolio includes companies like CarbonCure, which injects recycled CO₂ into concrete to reduce its carbon footprint, Normative, a platform that helps businesses track and manage their carbon emissions, and Ampd Energy, which electrifies construction sites to minimize pollution. Beyond financial backing, 2150 takes a hands-on approach, working closely with founders to scale their businesses and maximize impact. The firm’s ultimate goal is to build a portfolio capable of mitigating gigatonnes of CO₂ emissions, comparable to the entire annual output of countries like Germany and France. With strong backing from investors like Novo Holdings and the BMW Foundation, 2150 is positioned as a key player in the future of urban development, driving both commercial success and global sustainability.

3B Ventures is an impact-driven venture capital firm founded in 2017 with headquarters in Copenhagen, Denmark. The fund primarily focuses on solving global challenges through investments in key sectors like agribusiness, clean-tech, energy, and healthcare. It has a global reach, with a particular focus on markets in Malaysia, Europe, and the United States. The firm targets early-stage startups and seed-stage companies that are developing innovative solutions with potential for significant impact. 3B Ventures has been involved in notable investments like AnaCardio, a biopharma company focused on medical advancements, where they participated in a substantial $18 million funding round. The fund’s average deal size is around $18 million, indicating that it takes a substantial approach to backing its portfolio companies. Founded by James Digby and Jan-Cayo Fiebig, 3B Ventures is committed to not only providing capital but also delivering strategic support to help companies scale and solve large-scale global problems. The firm tends to look for entrepreneurs passionate about creating change, with business models that align with their vision for a sustainable and impactful future. They prefer to work with founders who have a clear path to growth and profitability, and they actively engage in nurturing these businesses through their extensive network and resources. Entrepreneurs looking to approach 3B Ventures are encouraged to present well-developed solutions with demonstrable traction in key markets.

3E Bioventures Capital is a prominent venture capital firm specializing in the life sciences sector, focusing on innovative therapeutic drugs and disruptive med-tech. Founded with a mission encapsulated in their name—Expertise, Efficiency, Execution—3E Bioventures actively invests in global health innovators and TechBio, aiming to disrupt conventional paradigms by integrating biology with technology​​. Notable investments include Aravive, which develops biologic drugs targeting tumor metastasis, and C4 Therapeutics, which pioneers small-molecule drugs that degrade disease-causing proteins. Their portfolio also boasts companies like Cytek, which offers a transformative flow cytometry platform, and Twist Bioscience, known for its advanced DNA synthesis technology​​. Geographically, 3E Bioventures operates with a global perspective, maintaining a strong presence in the US and China. They often participate in early-stage and growth-stage investments, providing significant support in both capital and strategic guidance​​. The firm’s team includes experienced professionals such as Li Jing, Frank Yan, and Linda Liu, who leverage their deep industry knowledge to support portfolio companies effectively. They emphasize a science-driven, entrepreneur-friendly approach, working closely with research institutions and companies to address unmet medical needs​. For startups seeking investment, 3E Bioventures looks for breakthrough innovations in biotech and med-tech, focusing on areas with strong medical needs and the potential for significant impact. They prefer to engage with companies that align with their strategic goals and demonstrate a clear pathway to success​​.

3M Ventures, the corporate venture capital arm of 3M, focuses on investing in early-stage companies that align with 3M's strategic priorities. These priorities include automotive electrification, safety, home improvement, consumer electronics, climate tech, sustainable packaging, industrial automation, and semiconductor and data center technologies. Their investment strategy targets companies with strong intellectual property, demonstrated commercial traction, and robust management teams​. Notable investments by 3M Ventures include GrayMatter Robotics, Moxe Health, and Metalenz, which span across artificial intelligence, healthcare, and 3D technology, respectively. 3M Ventures seeks to not only provide financial investment but also leverage 3M's extensive technological platforms, manufacturing capabilities, and global networks to help scale their partner companies​. 3M is also heavily committed to sustainability. The company has pledged $1 billion to achieve carbon neutrality, reduce water use, and improve water quality by 2030. This initiative includes implementing state-of-the-art water purification technology and developing innovative solutions for renewable energy and emissions reduction​.

3one4 Capital is a Bangalore-based early-stage venture capital firm with over $750 million in assets under management. Known for its disciplined investment strategy, the firm has successfully raised $200 million for its latest fund, focusing on technology-driven startups in sectors like SaaS, fintech, consumer internet, and enterprise digitization. Its portfolio includes notable companies such as Licious, Darwinbox, Open, Jupiter, and Koo. The firm was co-founded by Pranav and Siddarth Pai, who lead the charge in identifying and nurturing high-potential startups. They focus on early-stage investments, with typical checks ranging from $500K to $5 million, and offer LPs opportunities for direct co-investment. This deep engagement strategy allows 3one4 to maintain strong portfolio relationships from seed through growth stages. 3one4 also explores newer areas such as climate tech and digital health, aiming to back transformative companies that cater to India’s growing digital economy. With a proven track record of creating unicorns, the firm is one of the top-performing VC funds in India, boasting industry-leading returns. The team includes partners like Anurag Ramdasan and Nruthya Madappa, who bring their expertise to further scale portfolio companies.

3x5 Partners is a Portland, Oregon-based venture capital firm that focuses on investments in companies developing solutions for global health and climate challenges. Founded in 2011 by Tony Arnerich and Nicholas Walrod, the firm has raised over $400 million across multiple funds, including their most recent $100 million Fund III. 3x5 Partners primarily invests in late-stage (Series A/B) ventures within sectors such as biotechnology, medical devices, diagnostics, and clean technology. The firm is known for its commitment to long-term partnerships, often leading early investment rounds and providing significant follow-on funding. Notable investments include companies like Fervo Energy, Arch Oncology, and Smart Wires, all of which align with their mission to create meaningful social and environmental impact. 3x5 Partners differentiates itself by focusing on capital-intensive, high-impact ventures that are often overlooked by traditional venture capital firms. They take an active role in the companies they invest in, serving as board members and strategic partners to guide these ventures through critical growth stages. The firm's leadership team, which includes seasoned investors like Joe Biller and David Yeh, is deeply experienced in both impact investing and venture capital, ensuring that they not only generate strong returns for their investors but also contribute to solving some of the world's most pressing problems.

415 Capital is a Munich-based venture capital firm that specializes in investing in breakthrough medical technologies, particularly those addressing critical unmet needs in cardiovascular and neurovascular diseases. With a focus on improving patient outcomes and reducing healthcare costs, 415 Capital invests in startups across Europe, Israel, and North America, typically writing checks between €5 million and €15 million per company. The firm’s portfolio boasts several cutting-edge companies like Supira Medical, which is developing a percutaneous ventricular assist device for high-risk heart patients, and Distalmotion, known for its innovative surgical robotics platform. 415 Capital avoids biotech, healthcare services, and wellness products, honing in exclusively on medtech innovations. Their strategy emphasizes deep involvement from the R&D stage through commercialization, leveraging close relationships with healthcare providers and access to a €2 billion commercial channel in Europe. The firm’s team combines expertise in investment, medical device commercialization, and clinical practice, ensuring they remain at the forefront of medical innovation. Historically, 415 Capital has been part of significant advancements such as the development of transcatheter heart valves and renal denervation technologies. Their approach to venture capital is deeply rooted in the belief that pioneering medical technologies can simultaneously improve healthcare and generate substantial returns.

42CAP, established in 2016 and based in Munich, Germany, is a venture capital firm that focuses on seed-stage investments in B2B technology startups across Europe. The firm is notable for its emphasis on data-driven and SaaS companies, with a strong interest in applications of artificial intelligence and machine learning. Their portfolio includes notable startups like Adverity, a marketing analytics platform, and OnTruck, a real-time marketplace for truck deliveries. 42CAP typically invests between €0.5 million and €1.5 million per company and aims to back ventures that can scale globally from a European base. 42CAP's strategic approach involves partnering with visionary founders to drive technological innovations in B2B sectors. They seek companies that enable organizational agility and efficiency, particularly in fields such as big data and IoT. Their latest fund, totaling €50 million, is set to support approximately 20 startups, expanding on the success of their initial investments. The team behind 42CAP includes experienced entrepreneurs and investors like Alex Meyer and Thomas Wilke, who previously built successful companies such as eCircle and Relayr. This diverse and experienced team is integral to their hands-on approach in supporting portfolio companies from early stages to market leadership.

4BIO Capital is a London-based venture capital firm specializing in advanced therapies, particularly in areas like gene therapy, cell therapy, RNA-based treatments, and the microbiome. The firm is focused on addressing high unmet medical and social needs through early-stage investments in innovative life sciences companies. Founded by a team of experienced academics, physician-scientists, and industry executives, 4BIO Capital has built a strong reputation for its deep expertise in the rapidly evolving field of advanced therapies. The firm’s strategy involves not only backing early-stage startups but also creating new companies by leveraging cutting-edge research from academic institutions across Europe and the U.K. 4BIO Capital recently raised $50 million for its second advanced therapy VC fund, with plans to increase this to $150 million. This fund is dedicated to expanding the use of advanced therapies beyond rare diseases to treat more prevalent conditions like diabetes and rheumatoid arthritis. The firm has a global investment focus, with no geographical restrictions, though it emphasizes the untapped potential within U.K. institutions. The team at 4BIO includes managing partners Dmitry Kuzmin and Andrew Kozlov, who bring a wealth of knowledge and experience in life sciences and venture investing, helping to drive the firm’s mission of bringing transformative therapies to market​.

500 Global, formerly known as 500 Startups, is a prominent venture capital firm with a robust global presence and over $2.4 billion in assets under management. Since its inception in 2010, it has invested in more than 2,800 companies across 80+ countries. Some of its most notable investments include Credit Karma, Twilio, Canva, Grab, Bukalapak, The RealReal, Talkdesk, Udemy, and Ipsy​​. 500 Global's industry focus spans various sectors, with significant investments in consumer services, software-as-a-service (SaaS), fintech, and media​ (Proptech Zone)​. Its geographic focus is truly global, with operations in major innovation hubs such as Silicon Valley, New York, London, Singapore, and Mexico City, as well as emerging markets like Lagos, Jakarta, and Riyadh​​. The fund's strategy involves early-stage investments, providing seed capital along with comprehensive support through its Seed Accelerator Programs. These programs emphasize digital marketing, customer acquisition, lean startup methodologies, and fundraising strategies. 500 Global prefers to invest in companies with high growth potential and innovative business models​. Typically, 500 Global invests an average of $150,000 to $250,000 in initial seed rounds and often leads these rounds. The firm is known for its hands-on approach, leveraging its extensive network of mentors, industry experts, and alumni to support portfolio companies. Recently, 500 Global has been active in launching thematic funds targeting specific industries and regions, further expanding its investment reach​​. The leadership team includes Christine Tsai, the CEO and Founding Partner, who has steered the firm’s growth and global expansion. 500 Global's diverse team of over 100 members spans more than 30 countries, bringing a wealth of experience as entrepreneurs, investors, and operators from leading tech companies​.

5AM Ventures, established in 2002, is a prominent venture capital firm specializing in early-stage investments in life sciences. They have a significant presence in both San Francisco and Boston. The firm focuses on biopharmaceuticals, drug delivery technologies, and life science instruments. Their portfolio includes notable companies like Envoy, Epirus, Flexion, Homology Medicines, and Ideaya Biosciences, showcasing their broad impact across the healthcare sector. 5AM Ventures adopts a hands-on approach through their 4:59 Initiative, partnering with academics and entrepreneurs to incubate breakthrough science. They provide both venture capital for private therapeutic companies and public equity investments in small and mid-cap biotech firms. This strategy allows them to support companies from inception through to later stages of development and public offerings. Geographically, 5AM Ventures focuses on investments within the United States, fostering innovation in healthcare by backing companies that address critical medical needs through cutting-edge technology. Their recent exits include companies like Escient Pharmaceuticals and Impel Neuropharma, demonstrating their successful track record. The team at 5AM Ventures includes co-founders Andrew Schwab and John Diekman, along with managing partner Kush Parmar. Their combined expertise in science, medicine, and finance positions them as key players in shaping the future of life sciences. For startups looking to partner with a venture capital firm that offers deep industry knowledge and a robust network, 5AM Ventures presents a compelling opportunity to advance healthcare innovation.

645 Ventures, founded in 2014 and based in New York City, is an early-stage venture capital firm known for backing high-growth technology startups. The firm has a strong focus on sectors such as SaaS, digital health, e-commerce, and data infrastructure. Their portfolio includes notable companies like FiscalNote, a platform that helps organizations navigate legislation; Iterable, a cross-channel marketing platform; and Goldbelly, a food delivery service that specializes in regional delicacies. 645 Ventures invests in startups that leverage data to enhance customer experiences, transform traditional industries through software, and innovate within the engineering value chain. They are particularly interested in the second wave of SaaS applications, which address the evolving needs of distributed workforces and the adoption of technology in new business areas. The firm is co-founded by Nnamdi Okike and Aaron Holiday, who bring extensive experience and a hands-on approach to supporting their portfolio companies. This includes helping with customer acquisition, talent recruitment, and fundraising strategy. With a geographic focus primarily in the United States, 645 Ventures also maintains a presence in San Francisco to tap into the West Coast's innovation ecosystem. Their investments range from seed to Series B stages, and they actively lead rounds and provide follow-on funding.

6th Man Ventures (6MV) is a dynamic venture capital firm based in New York, specializing in early-stage investments within the web3 ecosystem. With a strong focus on crypto, tech infrastructure, and new economic models for media, entertainment, art, and games, 6MV is dedicated to supporting transformative projects in these sectors. Their investment portfolio includes notable companies like Magic Eden, io.net, and Livepeer. Founded in 2021 by Mike Dudas and Serge Kassardjian, the firm has quickly made a name for itself by investing in projects that push the boundaries of web3 technology. They are particularly interested in startups that demonstrate domain expertise, solve significant problems in large markets, and have a strong ability to execute and scale. 6th Man Ventures typically invests up to $5 million in pre-seed, seed, and Series A rounds, and their approach is hands-on, offering substantial added value through startup operations, marketing, communications, partnership introductions, and product iteration. They seek founders who are building web3-first projects with the potential for massive impact. The team at 6MV is composed of seasoned founders and operators who have deep empathy for the challenges startups face, providing strategic guidance and support to help them succeed. For startups looking to partner with 6MV, the firm prefers concise, clear pitches that highlight the project's unique insights and market potential.

7percent Ventures is a London-based venture capital firm founded in 2014 by ex-founders Andrew Scott and Andrew Gault. Specializing in early-stage investments, the firm focuses on deep-tech startups with transformative potential, often referred to as "moonshot" companies. 7percent Ventures targets industries such as AI, quantum computing, AR/VR, spacetech, and future computing. Their investment philosophy is driven by supporting highly ambitious projects that aim to disrupt entire industries. The firm typically invests at pre-seed, seed, and Series A stages, with a typical investment range of €100,000 to €1.5 million. Notable companies in their portfolio include Oculus VR, which was acquired by Meta, and Universal Quantum, a pioneer in quantum computing. They also have a strong transatlantic reach, with investments spanning both the U.K. and the U.S., particularly in Silicon Valley. 7percent Ventures’ partners bring over 150 years of combined experience as entrepreneurs and investors, offering not just capital but also strategic mentorship, leveraging their extensive networks to help startups scale. The firm emphasizes the importance of transformative innovation and risk-taking in achieving sector-defining success​.

7wireVentures, co-founded by Glen Tullman and Lee Shapiro, is a venture capital firm that invests in early-stage digital health companies. The firm focuses on empowering consumers with innovative health solutions and technologies. Notable investments from 7wireVentures include Livongo, a chronic care management company that was acquired by Teladoc in a significant $18.5 billion deal, and NOCD, which focuses on providing virtual therapy for obsessive-compulsive disorder. Other prominent portfolio companies include FOLX Health, which offers virtual healthcare for the LGBTQIA+ community, and Brightline, a tech-enabled behavioral health platform for children and families. Recently, 7wireVentures closed a $217 million Growth & Opportunity Fund to support their existing portfolio and invest in Series B and C companies. This new fund brings their total assets under management to over $500 million. The firm continues to focus on "consumer-first, tech-enabled health and care solutions," reflecting their commitment to driving the digital transformation of healthcare.

8VC is a dynamic venture capital firm that focuses on investing in cutting-edge technology and life sciences startups. Notable investments in their portfolio include industry leaders such as Flexport, Guardant Health, Joby Aviation, and Palantir. 8VC primarily targets sectors like healthcare, logistics, IT infrastructure, and defense, with a strong emphasis on transformative technologies that drive significant societal impact. Geographically, 8VC invests globally but has a particular focus on the United States. The firm's investment strategy is centered on early-stage companies, often leading funding rounds with check sizes ranging from $100K to $50M. 8VC is known for its hands-on approach, supporting entrepreneurs not just with capital, but also with deep operational expertise and a robust network. They actively participate in the development of their portfolio companies, sometimes even building companies from the ground up when necessary. Led by Joe Lonsdale, a co-founder of Palantir, 8VC's team includes seasoned professionals with diverse backgrounds in technology, finance, and entrepreneurship. The team operates out of multiple locations, including San Francisco and Austin, positioning them at the heart of the innovation ecosystem. Startups looking to engage with 8VC should be prepared to demonstrate a strong potential for societal impact and innovative technology solutions. The firm values direct, compelling pitches and prefers to be approached through warm introductions within their extensive network.

A Plus Finance, founded in 1998 and headquartered in Paris, is a private equity firm specializing in the management of Common Investment Funds for Innovation (FCPI) and Proximity Investment Funds (FIP). The firm focuses on investing in innovative sectors such as IT, media, security, real estate, audiovisual, industrial, and environmental fields. A Plus Finance's portfolio is diverse, including notable investments in companies like Biotulin, Industrie Ofen Service, and Anotherway. The firm is known for its significant exits, including companies like Adeunis RF, Extruflex, and Intequedis. A Plus Finance typically participates in investment rounds with other co-investors, contributing to the growth and expansion of its portfolio companies. Led by key figures such as co-founder Niels Court-Payen, managing director Fabrice Imbault, and senior partner Hervé Legoupil, the firm leverages its extensive industry expertise to support the development and scaling of innovative businesses. Their investment strategy focuses on sectors that promise high growth potential and transformative impact, ensuring a robust and dynamic portfolio.

AAF Management Ltd., founded in 2016 and headquartered in Washington, D.C., is a prominent early-stage venture capital firm. The firm focuses on pre-seed, seed, and Series A stage technology companies in North America, with particular emphasis on sectors such as fintech, healthcare, consumer tech, enterprise software, and deep tech. AAF Management has an impressive portfolio of over 120 venture-backed companies. Notable investments include Robinhood, Didi, Savage X Fenty, StockX, Figure, Reddit, Current, Synthego, Jasper, and Drata. The firm has also celebrated significant exits, such as CrowdStrike (NASDAQ: CRWD), TruOptik (acquired by TransUnion), Even Financial (acquired by MoneyLion), Prodigy (acquired by Upstart), Portfolium (acquired by Instructure), and HeyDoctor (acquired by GoodRx). The firm is backed by over 95 limited partners, including family offices, royal families, C-level executives, and hedge fund managers from the US, Europe, and MENA regions. AAF Management prides itself on its strategic value-add, leveraging a vast network to support its portfolio companies and emerging managers globally.

ABB is a global leader in electrification, automation, robotics, and motion technologies, aiming to drive sustainable industrial transformations. Headquartered in Switzerland, ABB operates in over 100 countries and employs around 105,000 people. Their solutions focus on increasing energy efficiency and improving productivity across a wide range of industries, from utilities and transport to infrastructure and manufacturing. ABB’s business is organized into four key areas: Electrification, Motion, Robotics & Discrete Automation, and Process Automation. These divisions help industries across the globe innovate and optimize their processes. For example, ABB's Robotics division is one of the world’s leading providers of robotics and machine automation solutions, integrating advanced technologies like AI and the Internet of Things (IoT) to support smarter factories. In addition to their core business, ABB is deeply involved in sustainability efforts. They are committed to reducing carbon emissions and supporting the transition to renewable energy, as seen in their contributions to electric vehicle (EV) infrastructure and sustainable transport solutions. ABB has partnered with organizations such as NASCAR to explore electrification in motorsports, furthering innovation in high-performance electric racing vehicles. The company’s strong focus on research and development has led to cutting-edge innovations, particularly in electrification, where they design energy-efficient solutions to power cities and industries sustainably. ABB's global footprint and long-standing commitment to innovation make them a key player in driving the future of industrial automation and clean energy.

Abenteuer Ventures is a Menlo Park-based venture firm that focuses on angel investments in emerging technologies across sectors like tech, bio-science, and space exploration. The firm actively invests in early-stage startups, emphasizing innovative solutions that have the potential to make a significant impact on industries and society. Abenteuer Ventures collaborates with various syndicates, including notable names like Flight VC and Hack VC, giving it access to a wide range of deals. Their portfolio includes companies across a diverse array of industries, such as Akash Systems, which pioneers satellite communications technology, DroneSeed, offering drone-based reforestation solutions, and BillionToOne, which develops genetic testing technologies. Abenteuer Ventures typically invests in companies that align with its mission to leverage technology for transformative change, supporting everything from smart robotics to advanced medical devices. The firm’s approach centers on helping startups navigate early challenges while providing access to a network of strategic partners and investors. Their investments usually focus on seed-stage rounds, and they continue to support portfolio companies through follow-on funding and expert guidance.

Abies Ventures is a Tokyo-based venture capital firm that specializes in deep tech investments, aiming to tackle global issues like environmental degradation and food shortages through science and advanced technologies. Established in 2017, the firm focuses on early-stage companies with innovative solutions in areas such as AI, robotics, quantum computing, and biotech. Their portfolio includes cutting-edge startups like Synspective, Telexistence, and Mighty Buildings, reflecting their commitment to building sustainable, tech-driven solutions. Abies Ventures leverages its strong global network, partnering with large corporations, research institutes, and government agencies to help startups scale internationally. The fund is led by experienced venture founders like Fuyuki Yamaguchi and Sota Nagano, who bring extensive expertise in venture investment and scaling companies across Japan and the U.S. Their investment strategy centers on fostering deep tech companies with high impact potential, particularly in areas where finance, technology, and market dynamics may not always align. Abies Ventures helps bridge these gaps by providing strategic advice and connecting startups with key players to enhance their growth trajectory​.

Abingworth, founded in 1973, is a transatlantic life sciences investment firm with a robust portfolio and a strategic focus on turning innovative science into transformative medical treatments. With offices in London, Boston, and San Francisco, Abingworth has invested in over 179 companies, resulting in 73 IPOs and 46 M&As. The firm operates across three main investment stages: seed and early-stage, development stage, and clinical co-development, and typically invests between $500,000 to $2 million in initial rounds, supporting portfolio companies through subsequent funding stages. Notable investments include Adaptate Biotherapeutics, Jasper, and Tizona Therapeutics. Abingworth's team, led by Managing Partners Tim Haines and Kurt von Emster, brings decades of experience in life sciences and venture capital. The firm is deeply embedded in key biotech hubs, facilitating productive interactions with entrepreneurs and access to top-tier scientific talent. The firm emphasizes long-term partnerships, providing not just capital but also strategic guidance in areas such as clinical development, regulatory approval, and commercialization. Abingworth's recent integration with Carlyle Group underscores its commitment to expanding its impact in the global healthcare investment ecosystem. Startups seeking investment from Abingworth should have groundbreaking science with the potential to materially improve patient outcomes. The firm values deep industry expertise, strong leadership, and a clear path to transformative impact.

Able Partners, founded in 2016 and based in New York City, is a venture capital firm that focuses on investing in early-stage companies aiming to improve daily lives through health and wellness. The firm is known for its support of passionate entrepreneurs and inspiring brands across various industries including consumer products, health tech, and wellness. Their diverse portfolio includes investments in companies such as Clare, a direct-to-consumer paint company; Alto Neuroscience, a company focused on precision psychiatry; Little Otter, a mental health service for children and families; and Kindred, a network for professional caregivers. Other notable investments are Beam Impact, Vivvi, and Capable Health. Able Partners has made over 60 investments and has achieved multiple successful exits. Key exits include Alto Neuroscience, Stretch*d, and Capable Health, showcasing their ability to support companies from early stages to successful outcomes. The firm is led by co-founders Lisa Blau and Amanda Eilian, who bring extensive experience in consumer-focused investments and entrepreneurship. Their investment strategy emphasizes not only providing capital but also leveraging their extensive networks and expertise to help portfolio companies achieve their full potential.

ABN AMRO Ventures, the corporate venture arm of ABN AMRO Bank, operates with €150 million under management, focusing on fintech, regtech, and sustainability-oriented tech solutions. Their investments emphasize scaling startups that bolster financial services through AI, blockchain, data analytics, and innovative SaaS models. With a strategic geographic focus on Europe, they selectively branch out to North America and Israel. Their strategy aims to bridge the banking ecosystem with cutting-edge solutions, preferring Series A and later-stage rounds with investments ranging from €2 to €15 million. ABN AMRO Ventures often co-invests but does not always lead rounds, positioning itself as a value-added participant that extends industry insights and networking opportunities. The fund boasts a strong portfolio, including prominent names like Tink, Quantexa, and solar finance enabler Laka. They prioritize partnerships that align with the bank's broader objectives of innovation and sustainability. The team, steered by Managing Director Hugo Bongers and a group of seasoned financial and tech experts based in Amsterdam, emphasizes accessible communication with founders and appreciates clear, data-driven pitches. Startups are advised to demonstrate robust market potential, scalable technology, and strategic alignment with banking needs to capture their interest. ABN AMRO Ventures actively engages in fostering innovation hubs and prefers targeted, well-researched approaches when founders seek to initiate contact.

Abstract Ventures is a San Francisco-based VC firm founded in 2016, focusing on early-stage investments across biotech, consumer products, crypto, and enterprise frontier tech. The firm has gained a reputation for backing innovative and high-potential startups, with a portfolio that includes successes like Rippling and Material, the latter achieving unicorn status in 2022. Abstract Ventures primarily targets investments within the U.S., engaging in Seed and Series A rounds with typical check sizes ranging from $5 to $15 million. Their strategy blends flexibility with strategic partnerships, often co-investing with other VCs and leading rounds when they see transformative potential. Abstract is known for being founder-friendly, offering not just capital but also access to a wide network of industry experts, experienced entrepreneurs, and investors who can provide significant strategic value. In 2024, Abstract maintained a proactive stance, completing 16 new investments in companies such as Unify and Thirddimension.ai. The firm’s small yet powerful team is spearheaded by founder and General Partner Ramtin Naimi, who, along with four other partners, leverages years of investment experience and market insight from their base in San Francisco. Abstract Ventures advises founders to approach with a robust market strategy, proven product traction, and genuine storytelling. Rather than solely evaluating polished decks, the firm seeks authenticity and conviction in a startup’s vision. They primarily source deals through referrals and their network, emphasizing relationships and strategic alignment. With this approach, Abstract has carved out a distinctive presence in the early-stage VC landscape, empowering founders from idea to growth phase.

Accel is a renowned venture capital firm known for its strategic investments across various stages and sectors. Founded in 1983, Accel has played a pivotal role in the success of numerous high-profile companies. Some of its most notable investments include Facebook, Dropbox, Spotify, and Slack, showcasing its strength in identifying and backing transformative technology companies early on. The firm's investment strategy focuses on seed and Series A funding, ensuring deep engagement with startups from their inception. Accel emphasizes a collaborative approach, providing not just capital but also mentorship and strategic support to help entrepreneurs build market-defining businesses. This hands-on involvement has led Accel to lead investments in over 70% of its portfolio companies​. Accel operates globally, with key offices in Silicon Valley, London, and Bangalore, enabling it to tap into entrepreneurial talent worldwide. The firm has recently closed on several funds totaling $3.05 billion, aimed at supporting early-stage startups and growth rounds for more mature companies​​. In 2023, Accel made significant investments in companies like Blackpoint Cyber, Headway, and Cyera, reflecting its commitment to diverse sectors such as cybersecurity, mental health, and data protection​​. This broad sector focus, combined with a global investment perspective, positions Accel as a key player in the venture capital landscape, continuously driving innovation and supporting exceptional entrepreneurs around the world.

Accelerace is one of the most prominent pre-seed investors and startup accelerators in the Nordics, headquartered in Copenhagen. Founded in 2008, it has supported over 700 startups, including high-profile companies like Trustpilot, Templafy, and Coinify. Accelerace focuses on providing early-stage startups with capital and mentorship, investing up to 1 million DKK through standardized convertible loans. Their investment strategy targets industries such as fintech, healthtech, climatetech, SaaS, and e-commerce, helping startups build scalable solutions across these sectors. The firm’s accelerator program is a comprehensive seven-week initiative designed to prepare startups for fundraising, offering support with pitching, business development, and investor connections. Startups that graduate from the program gain access to the Accelerace Allstars community, a lifelong network of successful founders and industry experts who provide ongoing mentorship and strategic advice. Notable alumni include Donkey Republic and Actimo, which both achieved successful exits. With over 600 investments and a solid presence in Denmark, the Baltics, and other European regions, Accelerace continues to play a pivotal role in shaping the future of innovation in Europe.

Accelerated Ventures, based in San Mateo, California, is a venture capital firm focused on early-stage investments in tech and life sciences. The firm has built a diverse portfolio that includes notable companies such as Telesentry, Amnesty, and Diag-X. Their investment strategy emphasizes sectors like HealthTech and retail, aiming to support innovative startups in these industries. With a portfolio count of six companies, Accelerated Ventures provides funding and strategic guidance to help these startups scale and succeed. Key investments like Telesentry and Diag-X highlight their commitment to fostering growth in tech and healthcare. The firm is led by experienced professionals who bring a wealth of knowledge and expertise to their investment approach, ensuring that each portfolio company receives the support needed to thrive in competitive markets.

Accion Venture Lab is an early-stage venture fund focused on empowering inclusive fintech startups that serve underserved and low-income populations globally. Established as part of Accion, a nonprofit dedicated to financial inclusion, Venture Lab provides seed-first capital paired with extensive strategic and operational support to help startups scale and overcome early challenges. Their diverse portfolio features innovative companies like Apollo Agriculture, which offers tech-driven financing to smallholder farmers in Kenya and Zambia, and Bababos, an Indonesian platform that supports small-scale manufacturers with raw materials and financing solutions. With a geographic reach that spans Latin America, the Caribbean, sub-Saharan Africa, the Middle East, North Africa, Southeast Asia, and even parts of the U.S., Accion Venture Lab's commitment is global. The fund targets industries such as digital lending, insurtech, personal financial management, and MSME-focused solutions, identifying startups with a mission to address systemic barriers to financial access. Their strategy is unique in that they prefer being the first institutional investor, ensuring startups receive not just capital but high-touch mentorship and strategic guidance. In 2019, Accion Venture Lab boosted its support efforts by launching a $23 million fund aimed at deepening their investment into inclusive fintech. Their approach prioritizes not only financial backing but also leveraging their deep-rooted expertise in financial inclusion to provide hands-on operational assistance. The team is led by seasoned Managing Partners Amee Parbhoo and Rahil Rangwala, who bring years of experience in fintech, impact investing, and scaling social enterprises. Founders looking for support from Venture Lab should demonstrate impactful, scalable solutions with clear pathways to financial inclusion.

Accomplice Ventures, founded in 2015 and based in Boston, Massachusetts, is a prominent seed-led venture capital firm. The firm specializes in technology startups across various sectors including cybersecurity, eSports, data analytics, SMB software, emerging hardware platforms, and marketplaces. Notable investments by Accomplice include leading tech companies such as DraftKings, AngelList, Carbon Black, CoinList, Currencycloud, and FreshBooks. Their portfolio also features innovative firms like Hopper, Patreon, PillPack, SecurityScorecard, Veracode, and WHOOP. Accomplice has a significant track record of successful exits, with companies like Datadog, Snap, and DraftKings achieving substantial market presence and growth. Accomplice operates with a unique federated VC model, supporting initiatives such as the operator-angel movement through Spearhead and the blockchain sector via Accomplice Blockchain. They are also anchor LPs in numerous solo GP funds, reflecting their commitment to a diverse and dynamic investment strategy. The firm was initially part of Atlas Venture before the tech and life sciences groups split, with Accomplice focusing solely on tech investments. They have raised multiple funds, including $405 million for their final fund as of 2022, ensuring a robust financial backing for their portfolio companies. Accomplice's investment philosophy is centered on being high conviction, concentrated, and patient investors, dedicated to helping founders build successful, market-leading companies​.

Ace Management Partners is a technology-driven investment firm specializing in high-potential pre-IPO companies across industries like AI, FinTech, and other disruptive technologies. Their thematic funds reflect a commitment to identifying transformative opportunities globally, with a focus on markets showing rapid innovation and growth. They prioritize transparency by integrating advanced technology and real-time data to provide investors with unparalleled insights and clarity in decision-making. Their strategy is bolstered by partnerships with market leaders who collectively have experience exceeding $30 billion in private company transactions. While their specific average check size isn’t publicly disclosed, they emphasize operational excellence, suggesting a proactive, well-calibrated investment approach. The team comprises experts passionate about innovation and fostering strategic partnerships, combining decades of private equity and venture capital expertise. With a strong base in New York, they leverage global market insights and local expertise to deliver exceptional results in the evolving pre-IPO landscape.

ACME Capital is a prominent venture capital firm based in San Francisco, specializing in early-stage investments in disruptive technologies and innovative business models. Founded in 2013 by Hany Nada, Shervin Pishevar, and Scott Stanford, the firm focuses on sectors such as healthcare, financial services, and space exploration. Their notable investments include high-profile companies like Uber, Slack, and DraftKings, demonstrating a knack for identifying and nurturing industry leaders. ACME Capital's investment strategy is centered on supporting visionary founders who are tackling large-scale challenges with groundbreaking solutions. They emphasize platform shifts and technology breakthroughs that promise significant societal benefits. The firm typically leads funding rounds and provides not just capital, but also strategic guidance and operational support to help startups scale effectively. Geographically, ACME Capital has a strong focus on the United States, but their portfolio also includes companies with a global reach. Their commitment to diversity and inclusion is reflected in their investment choices, with a significant portion of their portfolio companies led by underrepresented founders. The team at ACME Capital includes experienced partners like Brian Yee and Alexander Fayette, who bring a wealth of expertise and a hands-on approach to their investment process. Entrepreneurs looking to engage with ACME Capital are encouraged to present bold, transformative ideas that have the potential to disrupt massive markets and drive significant impact.

ACME Capital, founded in 2018 and headquartered in San Francisco, is an early-stage venture capital firm specializing in transformative technologies and business model innovations. They invest in deep tech, hardware, disruptive consumer products, enterprise solutions, fintech, health, and web3 sectors. Notable portfolio companies include IonQ, Braintrust, Cue Health, Astra, Uhnder, and Forte, which exemplify ACME’s commitment to pioneering advancements and societal benefits. ACME's strategy emphasizes partnering with founders from ideation through to IPO, offering not just capital but also strategic support and valuable industry connections. They favor investments in companies demonstrating significant market traction and a clear path to scalability. Their recent Fund IV and adjacent Opportunity Fund raised over $300 million, underscoring their robust position in the venture capital landscape. ACME is also dedicated to diversity and inclusion, with a substantial portion of their investments and team members representing historically underrepresented groups. Key team members include Co-founders Hany Nada and Scott Stanford, who bring extensive experience in venture capital and entrepreneurship, enhancing ACME’s ability to guide startups toward successful exits.

Acorn Pacific Ventures, founded in 2015, is a venture capital firm based in San Mateo, California. The firm focuses on early and growth-stage technology companies, with a particular emphasis on cross-border investments between the U.S. and Asia. Their portfolio spans industries like e-commerce, AI, fintech, and healthcare, including notable investments in Reap, a Hong Kong-based fintech company, and PopChill, an e-commerce fashion platform. Acorn Pacific is known for its strategic expertise in cross-border expansion, helping startups navigate both Silicon Valley and Asia-Pacific markets. The firm targets companies that leverage proprietary technology and tackle complex challenges in Industry 4.0 and global supply chain transformation. Their typical investment range varies, but they are active in funding rounds from seed to Series B. Led by Chih-Kai Cheng and a team of experienced partners, Acorn Pacific provides not only capital but also operational support to help companies scale. Their portfolio includes ventures like Nuohui Health, Avatar Medical, and Proglix, demonstrating their strong presence across various tech-driven sectors​.

Acre Venture Partners, founded in 2016 and based in Santa Monica, California, is a venture capital firm focusing on innovations in food and agriculture. Acre's diverse portfolio includes notable investments in companies like Meati Foods, which specializes in clean, fungi-based protein meats and raised $50M in a Series B round co-led by Acre. Mori is another significant investment, providing silk-based coatings for food protection to reduce waste and extend shelf life. Inari, a unicorn company developing advanced seed breeding technology, is valued at $1.5B. Spoiler Alert is a B2B marketplace helping food businesses manage surplus food, thus reducing waste. Agrofy is an online platform for farm equipment and infrastructure products. Acre's investment strategy emphasizes sustainability and technological innovation in agrifood technology. Recently, Acre closed its third fund at $140 million, targeting advancements in agricultural robotics, AI, and machine learning. This includes investments in companies like Bonsai Robotics and Farm-ng, focusing on automation in agriculture. Leveraging extensive experience and strategic partnerships, including advisory roles from industry experts like Lynda Deakin from IDEO and Chef David Chang, Acre drives growth and innovation within its portfolio companies. The firm supports startups from pre-seed to Series B stages, ensuring they have the necessary resources and strategic guidance to succeed in the evolving agrifood tech sector.

Acrew Capital is a venture capital firm founded in 2019 and headquartered in Palo Alto, California. The firm focuses on investing in companies across various stages, from early to growth stages, emphasizing diversity and transformative technology. Acrew Capital operates two primary funds: the Long Term View (LTV) fund, which targets early-stage investments, and the Diversify Capital Fund (DCF), which focuses on growth-stage companies. The LTV fund invests in early-stage companies, typically in the Seed to Series A stages, with check sizes ranging from $1 to $15 million. The DCF fund is designed for growth-stage investments, offering $10 to $20 million per investment. Acrew Capital's investment strategy prioritizes deep domain expertise, diverse perspectives, and long-term commitments to their portfolio companies. The firm's core thesis areas include financial services, cybersecurity, data, augmented reality, virtual reality, web 3.0, and cryptocurrency sectors. Acrew Capital's notable investments include companies like Eden Health, BlockFi, and CipherTrace. They have successfully exited several investments through mergers and acquisitions, demonstrating a strong track record in identifying and nurturing high-potential startups​. The leadership team at Acrew Capital is composed of experienced professionals like Lauren Kolodny, Mark Kraynak, and Asad Khaliq, who bring extensive experience in venture capital and entrepreneurship. The firm's commitment to diversity is reflected in its team composition and investment approach, with a significant portion of its leadership being women or people of color​.

Acrobator Ventures is an Amsterdam-based VC fund with a focus on early-stage investments, particularly in the Dutch, Baltic, and CEE regions. Founded in 2019 by Bas Godska and Joachim Laqueur, the firm is known for its strong emphasis on B2B SaaS, AI/ML, and data-driven startups. Acrobator’s strategy is distinctive, offering continuous support from pre-seed through IPO. They typically write checks ranging from $200k to $1.25 million and often lead investment rounds. The fund's portfolio includes notable companies like Glovo, Taxify, Pipedrive, and Planet42. Acrobator Ventures places a strong emphasis on bridging Eastern European startups with Western markets, leveraging their deep industry connections and market access. Key team members include Bas Godska, who has a strong background in marketing, and Mike Reiner, who focuses on scaling and go-to-market strategies. The team is split across Amsterdam, Kyiv, and Tbilisi, emphasizing their regional expertise. Acrobator prefers a hands-on approach, building long-term relationships with founders, which has contributed to successful investments like Respeecher and Let’s Enhance. Their flexible fund structure allows investors to opt into later rounds without being penalized, aligning the interests of all parties involved.

ACT Venture Capital, based in Dublin, Ireland, is an early-stage venture capital firm founded in 1994. The firm focuses on investing in high-potential technology companies across sectors such as AI, machine learning, enterprise software, deep tech, healthcare, and energy & climate. ACT has completed over 70 investments and manages around €627 million across multiple funds. Notable companies in ACT Venture Capital's portfolio include Cubic Telecom, a global connectivity management company; Ekco, a leading provider of cloud services; and Deciphex, which develops software solutions for digital pathology. The firm also backs companies like Gridbeyond, which focuses on intelligent energy management systems, and Provizio, an automotive safety technology company. ACT Venture Capital recently launched its sixth fund, ACT VI, with an initial close of €140 million, aiming to invest in 35 companies across its targeted sectors. This fund supports startups from seed to expansion stages, with the capacity to invest up to €10 million per company. The firm has a strong track record of successful exits, including the acquisition of SilverCloud Health by Amwell, Decawave by Qorvo, and Corvil by Pico. The leadership team at ACT includes John Flynn, Debbie Rennick, and John O’Sullivan, who bring extensive experience and expertise to the firm, supporting their portfolio companies through strategic guidance and robust networks.

ACT Venture Partners is an Amsterdam-based venture capital firm focusing on early-stage investments in deep-tech and enabling technologies across Europe, with additional strong ties to the Turkish market. They target sectors such as AI, IoT, data analytics, and healthcare, investing primarily during Seed and Series A rounds. ACT aims to back technically strong founders who are pioneering disruptive, market-transforming solutions. Some notable companies in their portfolio include Picus Security, Carbon Health, Eatron, and Nextmol. The firm typically leads seed rounds with checks up to €1 million, often continuing to support portfolio companies in subsequent funding rounds. Their investment strategy emphasizes hands-on collaboration, providing not only financial backing but also mentorship, networking, and strategic advice to help startups achieve critical product-market fit and scale. The core team comprises experienced professionals with backgrounds in engineering, finance, and entrepreneurship. Key figures include managing partners Erhan Kılıçözlü and Okan Kara, who bring decades of experience in tech transfer, venture capital, and innovation management, contributing to ACT's reputation as a value-adding partner for startups. ACT's approach involves close engagement from initial funding through to growth stages, leveraging their extensive network across Europe and beyond.

Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GlaxoSmithKline (GSK) in 2013. The firm focuses on advancing bioelectronic medicines and enabling technologies. APVC is headquartered in Cambridge, Massachusetts, with additional offices in Scotts Valley, California. APVC invests in companies that leverage advances in hardware, computing, and material science to regulate neural or cellular activity, aiming to treat a range of chronic diseases. Notable portfolio companies include Cala Health, which develops non-invasive neuromodulation therapies for conditions like essential tremor; CVRx, known for its FDA-approved BAROSTIM NEO therapy for heart failure; and Neuspera Medical, which is developing minimally invasive neuromodulation therapies for overactive bladder. The firm takes a hands-on role on the boards of startups, providing strategic guidance and support. APVC has made 25 investments to date, with recent notable investments in Exo, which offers AI-enabled handheld ultrasound imaging, and MicroTransponder, which focuses on therapies for neurological conditions. APVC's investment approach emphasizes diversity and inclusion within the healthcare and entrepreneurial communities. The leadership team includes Imran Eba and Juan-Pablo Mas, who bring extensive experience in venture capital and biotechnology investments.

Activant Capital, founded in 2015, is a venture capital firm that focuses on investing in companies during critical growth phases. With headquarters in Greenwich, Connecticut, and additional offices in New York, Berlin, and Cape Town, the firm has over $1 billion in assets under management. Activant Capital invests in various sectors, including fintech, supply chain, e-commerce, retail technology, and health tech. The firm has a strong portfolio featuring companies such as Boom Supersonic, DEUNA, Deliverr, Current, Finix, and Forter. Boom Supersonic is developing a new generation of supersonic commercial airliners, while Deliverr provides rapid e-commerce fulfillment solutions. Forter specializes in fraud prevention for online retailers, and Finix offers payment infrastructure for businesses. Activant Capital is known for its thesis-driven approach, concentrating on commerce infrastructure technology that enhances efficiency across industries. Their investment strategy emphasizes partnering with high-growth companies to redefine commerce systems. They provide extensive operational support to their portfolio companies, assisting with organizational structure, hiring, go-to-market strategies, and commercial introductions. The firm has also achieved several notable exits, including Hybris, which was sold to SAP for $1.4 billion, and Deliverr, highlighting their ability to identify and support transformative companies. Activant’s approach is to remain long-term partners, with fund lives extending up to 15 years to support the ambitious growth of their portfolio companies.

Activate Venture Partners, formerly known as Milestone Venture Partners, is an early-stage venture capital firm founded in 1999 and based in New York City. The firm focuses on investing in high-growth technology companies, particularly those in the healthcare and enterprise software sectors. Their strategy emphasizes being the first institutional investor in startups, with over 85% of their portfolio companies receiving pre-revenue investments​. Notable investments in their portfolio include companies like Healthify, Diameter Health, and Cureatr, reflecting their strong focus on healthcare technology. Additionally, they have invested in technology firms like Canvs.ai and Cloudnexa, which provide services ranging from market research to AWS management. Activate Venture Partners typically leads seed and early-stage financing rounds with initial investments often below $5 million. They are known for their hands-on approach, offering strategic guidance and support to help startups scale effectively. The leadership team includes co-founders Edwin Goodman and Todd Pietri, along with partners like Glen Bressner and Don Yount. Their extensive experience and deep industry connections provide valuable insights and resources to the companies they invest in​.